|1.||Van Bambeke, Françoise: 8 articles (12/2015 - 01/2004)|
|2.||Arhin, Francis F: 7 articles (12/2015 - 10/2008)|
|3.||Moeck, Gregory: 7 articles (12/2015 - 10/2008)|
|4.||Parr, Thomas R: 7 articles (10/2015 - 05/2003)|
|5.||Corey, G Ralph: 5 articles (12/2015 - 06/2014)|
|6.||Jones, Ronald N: 5 articles (02/2015 - 04/2012)|
|7.||Mendes, Rodrigo E: 5 articles (02/2015 - 04/2012)|
|8.||Sarmiento, Ingrid: 5 articles (01/2013 - 06/2009)|
|9.||Sader, Helio S: 4 articles (02/2015 - 04/2012)|
|10.||Moeck, Greg: 4 articles (01/2015 - 01/2013)|
01/01/2013 - "The safety and efficacy of a single 1,200-mg dose of the lipoglycopeptide oritavancin are currently being investigated in two global phase 3 studies of acute bacterial skin and skin structure infections. "
08/15/2015 - "Oritavancin is a lipoglycopeptide antibiotic that has been shown to be effective for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). "
10/01/2012 - "We previously demonstrated that 7 days of oritavancin instillation effectively treats Clostridium difficile infection (CDI) in a human gut model. "
01/01/2015 - "Concentration-time data were analyzed from two phase 3 clinical trials, SOLO I and SOLO II, in which oritavancin was administered as a single 1,200-mg dose to patients with acute bacterial skin and skin structure infections. "
01/01/2013 - "The pharmacology, unique pharmacokinetic-pharmacodynamic profile, and potential future role of oritavancin in combating multidrug-resistant infections are reviewed, with an emphasis on efficacy data from Phase II and III clinical trials. "
03/01/2006 - "Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia."
03/01/2006 - "aureus bacteremia and exposures for oritavancin, a novel bactericidal glycopeptide in development. "
06/01/2008 - "Currently, oritavancin has completed two Phase III trials and one Phase II trial for the treatment of complicated skin and skin structure infections, and two Phase II trials for the treatment of Gram-positive bacteremia. "
10/01/2009 - "A population pharmacokinetic model was developed to describe the disposition of oritavancin with data from a pooled population of phase 1 healthy subjects and phase 2 and 3 patients with complicated skin and skin structure infections or Staphylococcus aureus bacteremia. "
10/01/2009 - "Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia."
04/01/1998 - "Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis."
01/01/1999 - "Autoradiographic studies performed in rabbits with enterococcal endocarditis showed that 14[C]LY333328 was distributed heterogeneously throughout cardiac vegetations. "
12/01/2015 - "We describe the first use of a prolonged course of oritavancin in the treatment of a serious VRE infection, prosthetic valve endocarditis. "
02/01/2012 - "However, oritavancin had no substantial growth inhibitory effect against either VISA strain at high inoculum, suggesting that in rare VISA infections with an anticipated high bacterial burden such as endocarditis, alternative oritavancin dosing strategies, including combinations with other agents, may be explored."
04/01/1998 - "The in vivo efficacy of LY333328, a new glycopeptide antibiotic, was compared with that of vancomycin by using the rabbit model of left-sided methicillin-resistant Staphylococcus aureus endocarditis. "
|4.||Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis)
06/01/2003 - "In the rabbit model, LY333328 alone was an excellent treatment for cephalosporin-resistant pneumococcal meningitis, with a rapid decrease in colony counts and no therapeutic failures. "
06/01/2003 - "Using a rabbit model of meningitis, we sought to determine the efficacy of LY333328, a semisynthetic glycopeptide, in the treatment of cephalosporin-resistant pneumococcal meningitis. "
06/01/2003 - "Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis."
07/01/2001 - "In a rabbit model of Streptococcus pneumoniae meningitis single doses of 10 and 2.5 mg of the glycopeptide LY333328 per kg of body weight reduced bacterial titers in cerebrospinal fluid (CSF) almost as rapidly as ceftriaxone at 10 mg/kg/h (changes in log CFU, -0.29 +/- 0.21 and -0.26 +/- 0.22 versus -0.34 +/- 0.15/ml/h). "
04/01/2012 - "Once-daily intravenous administration of oritavancin was effective in methicillin-resistant Staphylococcus aureus (MRSA) endocarditis, penicillin-susceptible and cephalosporin-resistant pneumococcal meningitis in rabbits, staphylococcal and enterococcal central venous catheter infections in rats, and 24-hour postprophylaxis of inhaled anthrax in mice. "
04/01/2006 - "Investigations into oritavancin's efficacy will be explored in catheter-related bacteraemia and nosocomial pneumonia. "
08/01/2006 - "These compounds have proved effective for the treatment of infections caused by multidrug-resistant Gram-positive bacteria, including complicated skin and skin structure infections (oritavancin, telavancin and dalbavancin), bacteremia (oritavancin and dalbavancin) and nosocomial pneumonia. "
02/01/2007 - "Search terms included MRSA, nosocomial pneumonia, pulmonary infections, vancomycin, quinupristin/dalfopristin, linezolid, daptomycin, tigecycline, dalbavancin, oritavancin, and ceftobiprole. "
07/01/2009 - "Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). "
|5.||Anti-Bacterial Agents (Antibiotics)
|10.||iclaprim (AR 100)